Differential antiproliferative and proapoptotic properties of Sorafenib, Regorafenib, Lenvatinib, and Cabozantinib administered at a regular used in vitro dose (10 μM) in 3D and 2D cultured-differentiated HCC with different p53 status. This evidence concerns the gene TP53 and hepatocellular carcinoma.